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A B S T R A C T
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and devastating human malignancies. In
about 70% of PDACs the tumor suppressor gene TP53 is mutated generally resulting in conformational changes
of mutant p53 (mutp53) proteins, which acquire oncogenic functions triggering aggressiveness of cancers and
alteration of energetic metabolism. Here, we demonstrate that mutant p53 prevents the nuclear translocation of
the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) stabilizing its cytoplasmic locali-
zation, thus supporting glycolysis of cancer cells and inhibiting cell death mechanisms mediated by nuclear
GAPDH. We further show that the prevention of nuclear localization of GAPDH is mediated by both stimulation
of AKT and repression of AMPK signaling, and is associated with the formation of the SIRT1:GAPDH complex. By
using siRNA-GAPDH or an inhibitor of the enzyme, we functionally demonstrate that the maintenance of GAPDH
in the cytosol has a critical impact on the anti-apoptotic and anti-autophagic effects driven by mutp53.
Furthermore, the blockage of its mutp53-dependent cytoplasmic stabilization is able to restore the sensitivity of
PDAC cells to the treatment with gemcitabine. Finally, our data suggest that mutp53-dependent enhanced
glycolysis permits cancer cells to acquire sensitivity to anti-glycolytic drugs, such as 2-deoxyglucose, suggesting
a potential personalized therapeutic approach in human cancers carrying mutant TP53 gene.
1. Introduction
Pancreatic cancer is one of the most frequent causes of tumor-as-
sociated deaths, and its incidence has recently increased in the western
world [1]. Pancreatic ductal adenocarcinoma (PDAC) is the most
common type of pancreatic malignancy and has a poor prognosis, with
a dismal overall 5-year survival rate of 5% [2]. The standard che-
motherapy regimen is still based on gemcitabine [3] since the ever-
growing understanding of the complex genetic, epigenetic and meta-
bolic alterations as well as of the equally complex interplay of cancer
cells with stromal cells, immune cells and endothelial cells has not yet
resulted in a dramatic change in the overall outcome for PDAC patients
[4].
One of the most frequent alterations revealed in PDAC patients
(~70%) is the missense mutations of the TP53 tumor suppressor gene
generating mutant p53 isoforms (mutp53s), which can acquire new
biological properties referred as gain-of-function (GOF) [5]. In addition
to the loss of the tumor suppression function of wild-type p53 (WTp53),
GOF mutp53 proteins contribute to the maintenance and stimulation of
cancer cell growth through the acquisition of oncogenic functions [5,6].
Such GOF activities dramatically alter tumor cell characteristics, pri-
marily through their interactions with other cellular proteins and reg-
ulation of cancer cell transcriptional programs [7]. Several studies have
elucidated that mutp53s are able to modulate the expression of a set of
genes through direct interaction with a number of transcription factors,
such as NF-Y, E2F1, E2F4, NF-κB p65, NF-κB p50, SREBP1 and vitamin
D receptor, thus regulating a panel of biological processes ranging from
metabolic reprogramming to the inhibition of apoptosis addressed to
triggering of cancer progression [6,8–11]. In particular, mutp53 was
reported to promote glycolysis and glucose metabolism to stimulate
cancer cell growth [12,13], in contrast to the glycolytic inhibitory role
of the tumor suppressor WTp53. However, the precise molecular
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mechanisms involved in this aberrant regulation of metabolism by
mutp53 isoforms are still incomplete.
Intriguingly, in addition to their canonical roles in glycolysis, recent
studies gradually uncovered some non-metabolic functions of glycolytic
enzymes in tumorigenesis and regulation of cancer cell fate [14]. Spe-
cifically, beyond glycolysis several reports have demonstrated that the
enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) has a
variety of other functions, including DNA repair, transcriptional reg-
ulation, membrane fusion and transport, autophagy, and cell death
[15–17]. The pleiotropic roles of GAPDH are strictly associated to its
intracellular localization, which is not restricted to the cytosol for
glycolytic energy production. Indeed, GAPDH is detected in other
subcellular compartments, such as nuclei in which it exerts a critical
role in the regulation of cell death-related gene transcription, stimula-
tion of apoptosis and modulation of cell fate. Post-translational mod-
ifications of the enzyme, including phosphorylation, oxidation, acet-
ylation, glycosylation, poly ADP-ribosylation, and pyruvylation
[18–20], and/or its binding with other molecules [21] are mechanisms
described to be involved in the GAPDH nuclear translocation with
consequent induction of anti-proliferative effects. For these reasons
GAPDH has received considerable attention as an appealing drug target
for cancer therapy [22].
In the present study, we demonstrate that GOF mutp53 stabilizes
the cytosolic localization of GAPDH avoiding its nuclear transport. This
contributes to support glycolysis and lactate secretion conferring en-
hanced sensitivity of cancer cells to metabolic drugs, as the glycolytic
inhibitor 2-deoxyglucose. We further demonstrate that the mechanisms
promoted by mutp53 to prevent the nuclear translocation of GAPDH
and its nuclear cell death-related effects include AMPK inhibition and
AKT stimulation, as well as the enhanced interaction between GAPDH
and SIRT1.
2. Material and methods
2.1. Cell culture
Pancreatic adenocarcinoma PaCa3, Panc1 and AsPC1 cell lines were
grown in RPMI 1640 medium (Thermo Fisher, Milan, Italy), supple-
mented with 10% FBS and 50 μg/ml gentamicin sulfate (BioWhittaker,
Lonza, Bergamo, Italy), and incubated at 37 °C with 5% CO2. These cell
lines were kindly provided by Dr. Aldo Scarpa (University of Verona,
Italy) and previously characterized for their genetic profile [23]. The
clones C9 (mock) and H1 (stably expressing mutant p53-R273H) of the
p53-null H1299 cells were kindly provided by Dr. Riccardo Spizzo
(Centro di Riferimento Oncologico, National Cancer Institute, Aviano,
Italy). All the cell lines were routinely tested to confirm lack of Myco-
plasma spp. infection.
2.2. Drugs and chemicals
Gemcitabine (2′,2′-difluoro-2′-deoxycytidine; GEM) was provided
by Accord Healthcare (Milan, Italy) and solubilized in sterile bi-distilled
water. 2-deoxyglucose (2-DG) was obtained from Sigma (Milan, Italy),
solubilized bi-distillated sterile water and stored at −80 °C until use.
The GAPDH inhibitor (S)-benzyl-2-amino-2-(S)-3-bromo-4,5-dihy-
droisoxazol-5-yl-acetate (AXP3009) has been designed and synthetized
in the laboratory of Dr. Paola Conti at the Department of
Pharmaceutical Sciences (University of Milan, Italy). AXP3009 was
solubilized in methanol and stored at −80 °C. Bruno et al. previously
reported the chemical structure and the synthesis of AXP3009 com-
pound [24]. The AKT inhibitor (SH-5) and the AMPK activator (AICAr)
were obtained from Sigma, solubilized in DMSO and bi-distillated
sterile water, respectively, and stored at −20 °C until use.
2.3. Liposome-mediated transient cell transfection
Exponentially growing cells were seeded in 96-well plates or in
60mm cell culture plates. The ectopic expression of mutant p53 iso-
forms in AsPC1 p53-null cells was carried out transfecting pcDNA3-
mutp53R273H or pcDNA3-mutp53R175H expression vectors, or their
relative mock vector (pcDNA3). Wild-type and mutant p53 protein
expression was transiently knocked-down by transfection with
pRSUPER-p53 vector or its negative control (pRSUPER), kindly pro-
vided by Dr. Agami (The Netherlands Cancer Institute, Amsterdam).
The silencing transfections were carried out for 48 h using
Lipofectamine 3000 (Thermo Fisher), according to the manufacturer's
instructions. Knock-down of GAPDH expression was obtained by
transfecting cells with specific GAPDH small interfering siRNA or with a
siRNA-CTRL (negative control) purchased from Life Technologies. Cells
were transfected by siRNA at a final concentration of 50 nM using
Lipofectamine 3000.
2.4. Lentiviral cell transduction
To silence R273H mutp53 expression in Panc1 cells, we used
plasmid pLKO.1 puro-vector encoding TP53-shRNA (TRCN0000003756
Sigma-Aldrich) indicated as p53-SH1. As negative control we used a
non-target shRNA control (SHC016; Sigma-Aldrich) indicated as p53-
NT. To generate viral particles, 293FT cells (Thermo Fisher) were
transfected using pLKO.1 shRNA DNA vector together with ViraPower
Lentiviral Packaging Mix (pLP1, pLP2 and pLP/VSV-G) (Thermo
Fisher). Seventy-two hours later, viral supernatant was collected and
transducing units per ml of supernatant were determined by limiting
dilution titration in cells. A MOI (multiplicity of infection) of 5 to 1 (5
transducing viral particles to 1 cell) was used for transducing cells using
Polybrene (Sigma-Aldrich) at a final concentration of 8 μg/ml to in-
crease transduction efficiency. Twenty-four hours after transduction,
puromycin selection (2 μg/ml) was performed for 48 h and mutant
TP53-silenced cells were used for experiments.
2.5. Cell proliferation assay
Cells were seeded in 96-well plates (5×103 cells/well) and the day
after transfected with the indicated constructs (see figure legends) and
incubated with various compounds at the indicated conditions. At the
end of the treatments, cell growth was measured by Crystal Violet assay
(Sigma) according to the manufacturer's protocol, and absorbance was
measured by spectrophotometric analysis (A595nm).
2.6. Soft agar colony formation assay
Anchorage-independent growth was performed in soft agar. Briefly,
5×104 H1299 cells, mock and R273H clones, were resuspended in
complete DMEM medium containing 0.6% agarose low-gelling tem-
perature (A9045 - Sigma Aldrich, Milan, Italy) and seeded into 6-well
plates containing 1.5ml layer of solidified 1% agarose low-gelling
temperature. After seeding the cells were untreated or treated with
50 μM AXP3009. Culture medium (100 μl each well) was added twice
weekly. After 21 days, cells were fixed using a solution of 4% Crystal
Violet containing 1% ethanol. At the end of the growth period, colonies
were photographed with 10× objective under an automated micro-
scope (EVOS FL Auto, Thermo Fisher Scientific, Waltham, MA, USA
Italy).
2.7. Apoptosis assay
Cells were seeded in 96-well plates (5× 103 cells/well) and, the day
after, were transfected with the indicated constructs (see figure le-
gends) and incubated with various compounds at the indicated condi-
tions. At the end of the treatments, cells were fixed with 2%
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paraformaldehyde in PBS at RT for 30min, then washed twice with PBS
and stained with annexinV/FITC (Bender MedSystem, Milan, Italy) in
binding buffer (10mM HEPES/NaOH pH 7.4, 140mM NaCl and 2.5mM
CaCl2) for 10min at RT in the dark. Finally, cells were washed with
binding buffer solution and fluorescence was measured by using a
multimode plate reader (Ex485nm and Em535nm) (GENios Pro, Tecan,
Milan, Italy). The values were normalized on cell proliferation by
Crystal Violet assay.
2.8. Monodansylcadaverine staining and autophagosome formation assay
To quantify the induction of autophagy, cells were incubated with the
fluorescent probe monodansylcadaverine (MDC) (Sigma), accordingly
with the guidelines for studying autophagy [25]. MDC is a selective
marker for acidic vesicular organelles, such as autophagic vacuoles.
Briefly, cells were seeded in 96-well plates (5×103 cells/well) and
treated with various compounds as indicated in the figure legend. At the
end of the treatments, cells were incubated in culture medium containing
50 μM MDC at 37 °C for 15min. Cells were then washed with Hanks
buffer (20mM Hepes pH 7.2, 10mM glucose, 118mM NaCl, 4.6mM KCl,
and 1mM CaCl2) and fluorescence was measured using a multimode
plate reader (Ex340nm and Em535nm) (GENios Pro, Tecan). The values
were normalized on cell proliferation by Crystal Violet assay.
2.9. RNA isolation and quantitative real-time PCR analysis
Total RNA was extracted from 106 cells using TRIzol Reagent
(Thermo Fisher) and 1 μg of RNA was reverse transcribed using first-
strand cDNA synthesis. Real-time quantification was performed in tri-
plicate samples by SYBR Green detection chemistry with Power SYBR
Green PCR Master Mix (Applied Biosystems, Carlsbad, CA, USA) on a
7900 HT Fast Real-Time PCR System (Thermo Fisher). Normalization
was performed analyzing the ribosomal protein large P0 (RPLP0)
mRNA expression level. The primers used were: GAPDH For, 5′-ATCA
Fig. 1. Mutant p53 prevents GAPDH nuclear translo-
cation. A–C) Cytosolic and nuclear extracts were used for
Western blotting of GAPDH, α-tubulin and Lamin B1 in
Panc1 and PaCa3 cell lines transfected with pRSuper-p53
or mock vector, or in AsPC1 cells transfected with plas-
mids for R273H mutant p53 expression or its negative
control. α-tubulin and Lamin B1 have been used as con-
trols of the quality of the cytoplasmic and nuclear protein
fractions, respectively. The amount of nuclear GAPDH in
each extract was quantified using NIH Image J software
and normalized to the amount of Lamin B1. Statistical
analysis *p < 0.05 Shp53 vs ShCtrl in Panc1 cells and
*p < 0.05 R273H vs mock in AsPC1 cells. D) Transduced
Panc1 cells with vector encoding TP53-shRNA indicated
as SH1 or its non-target shRNA control indicated as non-
target (NT). In NT image, the GAPDH (green signal) is
mainly localized into the cytoplasm and on the cell
membrane. 48 h after transduction, the enzyme is visible
also into the nuclei (blue signal). Inset A: the cell is shown
with a higher magnification. This cell is presumably un-
dergoing apoptosis and the enzyme is clearly visible in-
side the nucleus (as shown by the orthogonal projection,
XZ and YZ). Inset B: in the shown cell, the GAPDH (green
spots) begins to localize in the nucleus as it can be ap-
preciated from the orthogonal projection XZ and YZ
(yellow squares). Scale bar: 10 μm. (For interpretation of
the references to color in this figure legend, the reader is
referred to the web version of this article.)
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GCAATGCCTCCTGCAC-3′; GAPDH Rev., 5′-TGGTCATGAGTCCTTCC
ACG-3′; RPLP0 For, 5′-ACATGTTGCTGGCCAATAAGGT-3′ and RPLP0
Rev., 5′-CCTAAAGCCTGGAAAAAGGAGG-3′. The thermal cycle reac-
tion was performed as follows: 95 °C for 10min followed by 40 cycles at
95 °C for 15 s and 60 °C for 1min. The average of cycle threshold of
each triplicate was analyzed according to the 2(−ΔΔCt) method. Three
independent experiments were performed for each assay condition.
2.10. Subcellular fractionation and immunoblot analysis
Cells were washed with PBS and scraped into hypotonic buffer
(10mM HEPES pH 8.0, 10mM KCl, 0.1% Igepal CA-630, 1.5mM
MgCl2, 1 mM NaF, 0.5 mM Na3VO4, 0.5mM DTT, 1mM PMSF and
1× protease inhibitor cocktail). The suspension was incubated on ice
for 10min and after centrifugation at 300×g for 10min at 4 °C, the
supernatant was used as the cytoplasmic fraction. The pellet was wa-
shed twice with PBS and reconstituted in RIPA buffer (100mM Tris HCl
pH 8.0, 1% Triton X-100,100mM NaCl, 0.5mM EDTA and 1× protease
inhibitor cocktail). The suspension was incubated on ice for 15min.
After centrifugation at 15,000×g for 10min, the resultant supernatant
was used as the nuclear fraction. To obtain whole cell lysates, cells were
harvested, washed in PBS, and re-suspended in lysis buffer in the pre-
sence of phosphatase and protease inhibitors (50mM Tris–HCl pH 8.0,
150mM NaCl, 1% Igepal CA-630, 0.5% Na-Doc, 0.1% SDS, 1mM
Na3VO4, 1mM NaF, 2.5mM EDTA, 1mM PMSF, and 1×protease in-
hibitor cocktail). After incubation on ice for 30min, the lysates were
centrifuged at 5000×g for 10min at 4 °C and the supernatant fractions
were used for Western blot analysis.
Protein extracts (50 μg/lane for whole cell lysate immunoblots and
5 μg/lane for cytoplasmic and nuclear cell lysate immunoblots) were
resolved on a 12% SDS-polyacrylamide gel and electro-blotted onto
PVDF membranes (Millipore, Milan, Italy). Membranes were blocked in
5% low-fat milk in TBST (50mM Tris pH 7.5, 0.9% NaCl, 0.1% Tween
20) for 1 h at room temperature (RT) and probed overnight at 4 °C with
anti-phospho(Ser473)-AKT (1:2000; Cell Signaling Technology,
Danvers, MA, USA, #4060), anti-AKT (1:1000; Cell Signaling #9272),
anti-α-tubulin (1:2500; Oncogene, La Jolla, CA, USA, #CP06-100UG),
anti-phospho(Thr172)AMPKα (1:1000) (Cell Signaling, #2535), anti-
AMPKα (1:1000) (Cell Signaling, #2603), anti-glyceraldehyde 3-phos-
phate dehydrogenase GAPDH (G-9) (1:1000; Santa Cruz #sc-365062),
anti-LaminB1 (A-11) (1:1000; Santa Cruz #sc-377000), anti-p53 (BP
53.12) (1:2000; Santa Cruz #sc-81168), anti-Sirt1(D739) (1:1000, Cell
Signaling #2493). The immunocomplexes were visualized by chemi-
luminescent substrates (Amersham Pharmacia Biotech, Milan, Italy)
using ChemidocMP imaging system (Bio-Rad Laboratories, Milan, Italy)
and the intensity of the chemiluminescence signal was quantified using
NIH Image J software (http://rsb.info.nih.gov/nih-image/).
2.11. Immunofluorescence imaging of GAPDH subcellular localization
After lentiviral transduction, Panc1 cells were fixed in 4% paraf-
ormaldehyde for 15min and, after 4 changes (10min each) of PBS,
were permeabilized with 0.1% Triton X–100 for 5min in PBS. To sa-
turate unspecific binding sites, the cells were incubated for 45min at
RT with a blocking solution containing 5% BSA and 0.05% Triton X-100
in PBS. Samples were then incubated overnight at 4 °C with anti-
GAPDH (1:250; Santa Cruz #sc-365062) primary antibody diluted in
blocking solution. After 3 washes with PBS (10min each), cells were
incubated for 1 h at RT in the dark with specific secondary antibodies
(1 μg/ml) conjugated with Alexa Fluor-488 (Molecular Probes, Eugene,
OR, USA). The incubation with secondary antibody was followed by
10min incubation at RT with 1 μg/ml of 4′,6-diamidino-2-phenylindole
dihydrochloride (DAPI, Sigma-Aldrich). Samples were mounted in anti-
bleaching medium (Dako Fluorescent Mounting Medium). The negative
control procedure omitted the primary antibody. Pictures were ac-
quired under a Leica TCS SP5 AOBS laser confocal microscope (Leica-
Microsystems, Wezlar, Germany). A 40×/1.25 NA oil-immersion ob-
jective (HCX PL APO 40×1.25 OIL UV, Leica-Microsystem) was used.
2.12. Immunoprecipitation assay
Cell extracts were solubilized in lysis buffer with 150mM Hepes
pH 7.5, 300mM NaCl, 1% Triton-×100, phosphatase and protease in-
hibitors. Cells were harvested and lysed in lysis buffer and cleared by
centrifugation. For each immunoprecipitation, 1 μg of antibody and
1 μg of rabbit or sheep IgG (Santa Cruz Biotech) as control were used.
To immunoprecipitate we used an anti-GAPDH antibody from Santa
Cruz (sc-365062). 1 mg of pre-cleared protein extracts were diluted in
lysis buffer containing 0.05% BSA and incubated with Dynabeads®
Protein G (Thermo Fisher) and antibodies, according to the manufac-
turer's instructions. Bead-bound immunocomplexes were rinsed with
lysis buffer and eluted in 50 μl of SDS sample buffer for Western blot-
ting. Immunoblotting was performed using the following primary an-
tibodies: anti-Sirt1 (D739) (1:1000, Cell Signaling #2493), anti-GAPDH
Fig. 2. Mutant p53 enhances GAPDH glycolytic activity and L-lactate se-
cretion. A) GAPDH activity was quantified in Panc1 and PaCa3 cells trans-
fected with pRSuper-p53 vector or its negative control for 48 h. Statistical
analysis *p < 0.05 Shp53 vs ShCtrl. B) Panc1 and PaCa3 cells were transfected
with pRSuper-p53 vector or its negative control for 48 h. L-Lactic acid level in
the culture medium has been analyzed by measuring the absorbance at 340 nm
and the L-lactic acid concentration has been calculated as detailed in Material
and methods. Statistical analysis *p < 0.05 Shp53 vs ShCtrl.
G. Butera et al. BBA - Molecular Cell Research 1865 (2018) 1914–1923
1917
(G-9) (1:1000; Santa Cruz #sc-365062), anti-α-tubulin (1:2500;
Oncogene #CP06-100UG).
2.13. L-Lactic acid quantification assay
AsPC1 cells were seeded in 96-well plates (5×103 cells/well) and
transfected for 48 h. At the end of the treatments, culture medium has
been harvested, centrifuged at 1500×g for 10min and diluted six-fold
in H2O. For each sample, 25 μl has been analyzed in a final reaction
volume of 500 μl (Megazyme, #K-LATE 07/14). Absorbance at 340 nm
has been read after 10min. The activation of the reaction and L-lactic
acid concentration (g/l) has been calculated according to the manu-
facturer's instructions. The amount of L-lactic acid secreted by the cells
in each sample was calculated by subtracting the amount of L-lactic acid
in the medium (without cells) from the amount of L-lactic acid in the
medium from each sample. The values obtained were normalized to the
number of cells in each well.
2.14. GAPDH activity
Cells were resuspended in 0.2ml of an ice-cold buffered solution
containing 200mM NaCl, 1 mM EDTA, 20mM CHAPS and 10% sucrose
at pH=7 and disrupted with three freeze-thaw cycles. The total soluble
protein content of the cell lysates was assessed by measuring the ab-
sorbance at 280 nm using a Cary4000 spectrophotometer (Agilent
Technologies). Aliquots of 10 μl were assayed for GAPDH activity using
a modified version of the Ferdinand assay [26] in a buffered solution
containing 10mM triethanolamine, 10mM sodium arseniate, 5 mM
EDTA, 1.5 mM NAD+ and 2.2mM DL-glyceraldehyde 3-phosphate.
NADH formation at 25 °C was monitored at 340 nm. Each assay was
carried out at least in duplicate. The initial velocity was determined by
linear fitting of the initial phase of the kinetics. The ratio between
GAPDH activity and total soluble protein content was calculated for
each cell lysate.
Fig. 3. Prevention of nuclear localization of
GAPDH by mutp53 is mediated by regulation of
SIRT1:GAPDH complex and of AMPK and AKT
pathways. A) Cell lysates from p53-null H1299
cancer cells (C9 clone) and H1299 stably expressing
R273H mutp53 (H1 clone) were used to perform
Western blotting by loading 30 μg of protein extracts
and probed with the indicated antibodies. Left panel:
GAPDH was used as control of equal protein loading.
Right panel: GAPDH was immunoprecipitated from
protein extracts of H1299 cell C9 clone (mock) or H1
clone stably expressing R273H mutp53 using anti-
mouse GAPDH antibody (IP: GAPDH) and Western
blotting was performed using anti-SIRT1 antibody.
Negative control (Ctrl−) corresponds to lysis buffer
without protein extracts immunoprecipitated with
anti-GAPDH as described for mock or R273H sam-
ples. Protein extracts from H1299 cells (C9 mock
clone) were also immunoprecipitated with an equal
amount of mouse IgG as control. The blot exhibits
equivalent GAPDH levels and the absence of α-tu-
bulin expression in C9 and H1 clone samples as
control of the quality of the immunoprecipitation. B)
Western blotting was performed using 40 μg of
whole cell protein extracts from AsPC1 transfected
with plasmids for R273H mutant p53 expression or
its negative control (mock) and probed with the in-
dicated antibodies. For quantitative analysis, bands
were quantified using NIH Image J software and
normalized to the amount of GAPDH. Statistical
analysis * p < 0.05 R273H vs mock. C) AsPC1 cells
were transfected with the vectors for the ectopic
expression of p53-R273H or its mock control for 48 h
and treated with 2mM AICAr for 72 h or 15 μM SH-5
for 48 h. Western Blot analysis was performed using
whole cell extracts of AsPC1 and probed with the
indicated antibodies. α-tubulin and Lamin B1 have
been used as controls of the quality of the nuclear
protein fraction. Statistical analysis *p < 0.05
R273H vs mock; #p < 0.05 R273H+AICAr vs
R273H; §p < 0.05 R273H+SH-5 vs R273H. D)
AsPC1 cells were transfected with the vectors for the
ectopic expression of p53-R273H or its mock control
for 48 h and for the knock-down of GAPDH using
50 nM siRNA-GAPDH for 48 h. AsPC1 cells were
treated 2mM AICAr for 72 h or 15 μM SH-5 for 48 h.
L-Lactic acid level in the culture medium has been
analyzed as detailed in Material and methods. Sta-
tistical analysis *p < 0.05 R273H vs mock;
#p < 0.05 R273H+ siGAPDH vs R273H;
§p < 0.05 R273H+AICAr vs R273H; $p < 0.05
R273H+SH-5 vs R273H.
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2.15. Statistical analysis
ANOVA analysis with GraphPad Prism 5 software or two-tailed t-test
were used to calculate p values. Statistically significant results were
referred with a p-value< 0.05. Values are the means of three in-
dependent experiments (± SD).
3. Results
3.1. Mutant p53 prevents GAPDH nuclear translocation
To study the functional role of mutp53 proteins in the regulation of
the intracellular distribution of GAPDH, we modulated p53 expression
in PDAC Panc1 and PaCa3 cell lines having mutant or WT TP53 gene,
respectively, by using liposome-mediated transient transfection assay
and we analyzed the abundance of GAPDH in the cytosolic and nuclear
fractions of the cells. When Panc1 cells were knocked-down for mutp53
expression (left panel), the GAPDH expression level in the nuclear
fraction increased revealing a role for mutp53 in the prevention of the
nuclear translocation of the enzyme (Fig. 1A). Consistent with this, the
exogenous expression of R273H mutp53 in AsPC1 cells (null for p53
expression) (left panel) produced a drastic decrease of the GAPDH ex-
pression in nuclei (Fig. 1B). To investigate whether this is a phenom-
enon specifically acquired by mutant proteins we knocked-down
WTp53 (left panel) and analyzed cytosolic and nuclear GAPDH dis-
tribution, revealing that the WTp53 counterpart was not able to reg-
ulate the enzymatic nuclear translocation (Fig. 1C). To check the purity
of cytosolic and nuclear subcellular fractions we tested the abundance
of α-tubulin and of Lamin B1, which are specifically expressed in cy-
tosol and nucleus of the cells, respectively (Fig. 1A–C). We further
strengthened these data through lentivirus-mediated transduction and
immunofluorescence analysis by confocal microscopy using a different
sequence to knock-down mutant p53 expression (p53-SH1) or its ne-
gative non-targeted control (p53-NT) in PDAC Panc1 cells. Fig. 1D
shows that mutp53 silencing unchanged the expression level of GAPDH
(right panel), but it prompted GAPDH nuclear positivity as revealed
also by XY, XZ and YZ orthogonal projections of confocal images.
Fig. 4. GAPDH cytosolic stabilization contributes
to the oncogenic effects of mutp53. A) Cell pro-
liferation was measured by Cristal Violet assay and
B) apoptosis was determined by the annexinV
binding assay. AsPC1 cells were transfected with
plasmids for R273H mutant p53 over-expression or
its mock vector and for the knock-down of GAPDH
using 50 nM siRNA-GAPDH for 48 h. The cells were
also treated with 100 μM AXP3009 compound for
48 h. Statistical analysis *p < 0.05 R273H vs mock;
#p < 0.05 R273H+AXP3009 vs R273H;
§p < 0.05 R273H+ siGAPDH vs R273H. C)
Representative images of soft agar colony assay.
Upon 21 days of H1299 cell culture, the number of
colonies in mock cells and mutp53 R273H cells,
untreated or treated with 50 μM AXP3009, was
quantified by ImageJ software after staining with
Crystal Violet. Results were shown as mean ± SEM
of three independent experiment (right panel). Scale
bar: 200 μm. Statistical analysis *p < 0.05 R273H
vs mock; #p < 0.05 R273H+AXP3009 vs R273H.
D) Autophagosome formation assay through the in-
corporation of the MDC probe in AsPC1 cells trans-
fected and treated with 2mM AICA-R for 72 h or
15 μM SH-5 for 48 h. Statistical analysis *p < 0.05
R273H vs mock; #p < 0.05 R273H+AICAr vs
R273H; §p < 0.05 R273H+SH-5 vs R273H. E)
Autophagosome formation assay in Panc1 cells
transfected with pRSuper-p53 vector (Shp53) or its
negative control (ShCtrl), in the absence or presence
of siRNA-GAPDH for 48 h. Statistical analysis
*p < 0.05 shp53 vs shCtrl; #p < 0.05
shp53+ siGAPDH vs shp53.
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3.2. Mutant p53 enhances GAPDH glycolytic activity and L-lactate secretion
We further explored whether the stabilization of cytosolic GAPDH
by mutp53 resulted in an enhanced glycolytic activity of the enzyme.
Consistent with results reported in Fig. 1, Fig. 2A shows that mutp53
knock-down in Panc1 cells decreased GAPDH activity, which remained
unchanged after WTp53 silencing in PaCa3 cells. Overall, in our ex-
perimental model we observed that WTp53 and mutp53 have dual
opposite effects on the secretion of L-lactate, the metabolic compound
generated by the glycolytic pathway. Fig. 2B shows that L-lactate se-
cretion was enhanced by mutp53, consistent with the cytosolic stabi-
lization of GAPDH, while the WTp53 counterpart produced an in-
hibitory effect on L-lactate secretion, consistent with its overall negative
effects on glycolysis [27].
3.3. Prevention of nuclear localization of GAPDH by mutp53 is mediated by
regulation of SIRT1:GAPDH complex and of AMPK and AKT pathways
Since it has been described that the binding of SIRT1 to GAPDH re-
tains the latter protein in the cytosol as a mechanism to protect cytosolic
GAPDH from nuclear translocation [21], we investigated whether
mutp53 might stimulate SIRT1:GAPDH interaction. The large amount of
protein extract used for the immunoprecipitation assay was obtained by
a clone of H1299 cancer cells stably expressing R273H mutp53, which
we already used to study the oncogenic effects of mutp53s [28]. Fig. 3A
shows that H1299 cancer cells stably expressing R273H mutp53 pre-
sented enhanced levels of SIRT1 as compared to a mock clone of the
same cells (left panel). Furthermore, immunoprecipitation assay revealed
that SIRT1:GAPDH interaction was increased in R273H mutp53
expressing cells, as compared to mock (right panel), suggesting an in-
volvement for this complex in the prevention of nuclear localization of
GAPDH driven by mutp53 in cancer cells.
Moreover, since GAPDH cellular distribution can also be regulated
by post-translational modifications of the enzyme, we tested whether
mutp53 can modulate AMPK and AKT signaling pathways, which are
described to be involved in GAPDH phosphorylation in different amino
acidic residues of the enzyme resulting in the inhibition or in the sti-
mulation of GAPDH nuclear translocation, respectively [29,30]. Fig. 3B
shows that mutp53 overexpression in p53-null PDAC AsPC1 cells
strongly stimulated AKT signaling (P-AKT/AKT ratio) and inhibited
AMPK signaling (P-AMPK/AMPK ratio). To investigate the role of
AMPK and AKT regulation on the prevention of nuclear localization of
GAPDH by mutp53 we treated cells with the AMPK activator AICAr or
with the AKT inhibitor SH-5. Fig. 3C reports that the decrease of nuclear
GAPDH by mutp53 was recovered by AICAr or SH-5 treatment. Ac-
cordingly, the increased level of secreted L-lactate by mutp53 was re-
versed after GAPDH silencing or cell treatment with AICAr or SH-5
(Fig. 3D). Altogether these results demonstrated that mutp53 adopted
different mechanisms to prevent GAPDH nuclear translocation sus-
taining cytosolic glycolysis, as the interaction of the glycolytic enzyme
with SIRT1 as well as the inhibition of AMPK and stimulation of AKT
pathways.
3.4. GAPDH cytosolic stabilization contributes to the oncogenic effects of
mutp53
To investigate the functional role of GAPDH cytosolic stabilization
on the oncogenic effects of mutp53 we tested PDAC cell proliferation
Fig. 5. GAPDH cytosolic stabilization confers
chemoresistance to gemcitabine and sensitizes
cells to 2-deoxyglucose. A) Cell proliferation was
measured by Cristal Violet assay in AsPC1 trans-
fected cells and treated with 1 μM gemcitabine
(GEM) for 48 h. Statistical analysis *p < 0.05
mock+GEM vs mock; #p < 0.05 R273H+GEM vs
mock+GEM; §p < 0.05 R273H+GEM+
siGAPDH vs R273H+GEM. B) Cell proliferation was
measured by Cristal Violet assay in WTp53 PaCa3
cells and mutp53 Panc1 cells transfected with siRNA
GAPDH and/or treated with 1 μM gemcitabine
(GEM) for 48 h. #p < 0.05 siGAPDH vs CTRL;
*p < 0.05 GEM vs CTRL; §p < 0.05
siGAPDH+GEM vs GEM. C) Cell proliferation was
measured by Cristal Violet assay in AsPC1 cells
transfected as indicated and treated with 5mM 2-DG
for 48 h. Statistical analysis *p < 0.05 R273H+2-
DG vs R273H.
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and apoptosis after R273H mutp53 overexpression in AsPC1 cells with
the concomitant inhibition of the cytosolic glycolytic activity of GAPDH
by the AXP3009 compound or after GAPDH siRNA transfection for gene
silencing. The effective capability of AXP3009 to inhibit GAPDH ac-
tivity in PDAC cells and the silencing of GAPDH gene expression by
siRNA were reported in Supplementary Fig. 1A and B, respectively.
Fig. 4A and B show that a non-toxic concentration of AXP3009 or cell
transfection with GAPDH siRNA reversed R273H mutp53-dependent
PDAC cell hyperproliferation and apoptosis inhibition, respectively. To
confirm the role of GAPDH cytosolic stabilization on the oncogenic
effects of mutp53 we performed anchorage-independent soft agar
colony assay. Fig. 4C shows that R273H mutp53 favors the formations
of the colonies (as compared to mock cells) and that AXP3009 treat-
ment strongly reversed this phenomenon in R273H cells. Similar results
have been observed also for R175H mutp53-dependent modulation of
cell growth and apoptosis (Supplementary Fig. 2A and B), extending the
concept that GAPDH cytosolic stabilization may contribute to the on-
cogenic effects also of other GOF mutp53 isoforms.
Moreover, since we previously demonstrated that oncogenic effects
of mutp53 in PDAC cells are mediated also by the counteraction of
autophagy [28] and that mutp53s stimulate resistance to the drug
gemcitabine in PDAC cells [31], we here investigated whether GAPDH
activity might contribute to regulate also these phenomena. In Fig. 4D
we demonstrated that mutp53 decreased the amount of intracellular
autophagic vesicles and this event was completely reversed by the ad-
dition of the AMPK activator AICAr or the AKT inhibitor SH-5, which
also restored GAPDH nuclear prevention by mutp53 (Fig. 3C) and re-
duced L-lactate secretion prompted by mutp53 (Fig. 3D). In accordance
with these observations, the shp53-induced increase of autophagy was
counteracted in GAPDH silencing conditions in Panc1 cells, confirming
the involvement of GAPDH in the inhibition of autophagy by mutp53
(Fig. 4E). Altogether, these data indicate that GAPDH expression and its
glycolytic activity are required to mediate several oncogenic effects of
mutp53, including cancer cell hyper-proliferation, blockage of apop-
tosis and autophagy.
3.5. GAPDH cytosolic stabilization confers chemoresistance to gemcitabine
and sensitizes cells to 2-deoxyglucose
Concerning drug chemoresistance, we demonstrated that GAPDH
knock-down by siRNA restored PDAC cell sensitivity to gemcitabine even
in mutp53-overexpressing conditions (Fig. 5A). Furthermore, we tested
the role of GAPDH in PDAC cells endogenously expressing wild-type p53
or R273H mutp53. Fig. 5B shows that GAPDH silencing had an un-
detectable effect on gemcitabine sensitivity of WTp53 cells PaCa3 cells,
while it enhanced the response to gemcitabine of mutp53 Panc1 cells.
Furthermore, we aimed to investigate whether PDAC cells bearing
mutp53 might be more sensitive to the glycolytic standard inhibitor 2-
DG, accordingly with the stimulatory role of mutp53 on glycolysis via
GAPDH cytosolic stabilization. To functionally demonstrate the in-
volvement of mutp53 on PDAC cell sensitivity to 2-DG, we evaluated
the response of the cells after overexpression of R273H mutp53. Our
data reported in Fig. 5C show that mutp53 overexpression conferred to
p53-null AsPC1 cells a strong sensitization to 2-DG incubation, as
compared to its negative mock control. These results demonstrated that
targeting the glycolytic pathway may represent a potential therapeutic
opportunity for cancer patients bearing mutations in the TP53 gene.
4. Discussion
In addition to their canonical roles in glycolysis, recent studies
uncovered some non-metabolic functions in tumorigenesis of glycolytic
Fig. 6. Model of the insights identified in the present study.
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enzymes, including GAPDH, providing important insights into the
regulation of cancer cell growth and energetic metabolism [14]. Apart
from glycolysis, GAPDH participates in apoptosis, autophagy, iron
metabolism, membrane trafficking, histone biosynthesis, maintenance
of DNA integrity and receptor mediated cell signaling. As such, GAPDH
is not only a cytosolic protein but it can be detected in the membrane,
the nucleus, polysomes, the ER and the Golgi of the cells [32]. GAPDH
nuclear translocation is a particularly critical event in the light that,
although the enzyme contains a nuclear export signal, it does not
contain an equivalent nuclear localization signal. It has been demon-
strated that a variety of post-translational modifications as well as
protein-protein interactions are phenomena involved in the nuclear
translocation of the enzyme [33], leading changes in gene expression
profile and apoptosis in a number of cell systems [34,35]. Blocking this
translocation was found to be sufficient to reduce cytotoxicity in cancer
cells and to increase glycolytic activity, which is generally associated to
cancer cell survival [17,36], thus GAPDH is also considered an attrac-
tive therapeutic target against cancer [37].
It is emerging that mutp53 proteins, contrarily to their wild-type
p53 counterpart, stimulate glucose uptake and the Warburg effect of
cancer cells, resulting in abnormal glycolytic pathway and cancer
progression [38–40]. In the present study, we demonstrate that mutant
p53 stimulates glycolysis and lactate secretion through the cytosolic
stabilization of GAPDH, as schematically represented in Fig. 6. In par-
ticular, we show that mutant p53 can induce the expression of SIRT1,
an evolutionary conserved deacetylase enzyme [41,42], which stimu-
lates the proliferation and the expression of glycolytic genes in pan-
creatic neoplastic lesions [43]. In accordance with these observations,
our data show that mutp53 stimulates lactate secretion with the con-
comitant upregulation of SIRT1 expression and the formation of
SIRT1:GAPDH complex, which is reported to protect cytosolic GAPDH
from nuclear translocation after various stimuli, retaining the glycolytic
enzyme in the cytosol and promoting cell survival [21]. In line with
this, Ventura et al. published that acetylation in various lysine residues
of GAPDH is required for the nuclear translocation of the enzyme [44].
This would suggest that mutant p53 can protect cytosolic GAPDH from
nuclear translocation through SIRT1-GAPDH binding and the con-
sequent deacetylation of GAPDH. Furthermore, we reveal that another
mechanism by which mutant p53 stabilizes GAPDH cytosolic localiza-
tion is due to the stimulation of AKT and inhibition of AMPK signaling
pathways, which are reported to directly phosphorylate GAPDH in
different amino acidic residues with opposite effects on the nuclear
translocation of the enzyme. Indeed, it has been previously demon-
strated that AKT suppresses GAPDH-mediated apoptosis in ovarian
cancer cells via phosphorylating GAPDH at Thr237 and decreasing its
nuclear translocation [30], while AMPK stimulates the nuclear locali-
zation of GAPDH acting as a nuclear import signal [29]. We also de-
monstrate that the prevention of nuclear localization of GAPDH con-
tributes to the oncogenic effects driven by mutant p53 in pancreatic
cancer cells, as hyperproliferation, blockage of apoptosis and autop-
hagy. Finally, a crucial evidence of the present manuscript is the de-
monstration that GAPDH is functionally involved in the mutp53-de-
pendent chemoresistance to gemcitabine of PDAC cells.
Therapeutically, the inhibition of GAPDH in order to restore PDAC cell
sensitivity to gemcitabine may assume a critical relevance.
5. Conclusions
In conclusion, previous studies and the data of the present manu-
script demonstrate that mutp53 isoforms contribute to enhance the
glycolytic pathway in cancer cells through a coordinated regulation of
both the expression and the subcellular localization of glycolytic en-
zymes, including the prevention of nuclear localization of GAPDH, thus
favoring ATP production and the formation of metabolic intermediates
for cancer cell growth. Intriguingly, from a therapeutic point of view,
the stimulation of glycolysis by mutant p53 might represent an
“Achilles heel” of cancer cells carrying mutant TP53 gene, as revealed
by the mutp53-dependent acquisition of cell sensitivity to the treatment
with the glycolytic inhibitor 2-DG. Our results suggest that cancer cells
expressing mutant p53 proteins can be significantly more sensitive to
glycolytic drugs, as compared to the wild-type counterpart, providing
new therapeutic opportunities to be further considered for clinical
studies in cancer patients bearing mutant TP53 gene.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.bbamcr.2018.10.005.
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